This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Type 2 Diabetes Mellitus, Cardiovascular Diseases
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
-
Romain S. Neugebauer, Oakland, California, United States, 94612
Kaiser Permanente Southern California, Pasadena, California, United States, 91101
Kaiser Permanente Hawaii, Honolulu, Hawaii, United States, 96817
Henry Ford Health System, Detroit, Michigan, United States, 48202
HealthPartners Institute, Bloomington, Minnesota, United States, 55425
Geisinger, Danville, Pennsylvania, United States, 17821
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 85 Years
ALL
No
Kaiser Permanente,
Romain S. Neugebauer, PhD, PRINCIPAL_INVESTIGATOR, Kaiser Permanente
Patrick J O'Connor, MD, MA, MPH, PRINCIPAL_INVESTIGATOR, HealthPartners Institute
2025-08-31